Economic evaluation of cancer treatments: A review of the methods

Clinical Oncology

Volumn 11, Issue 2, 1999, Pages 78-83

  Brown, J ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER MORTALITY; CANCER THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC EVALUATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0033067131     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9018     Document Type: Review

References (42)

1. Buxton M. Scarce resources and informed choices. Ashton D. Future trends in medicine. 1993;36-39 Royal Society of Medicine Press, London:
2. Drummond M F, O'Brien B, Stoddart G L. Methods for economic evaluation of health care programmes. 1987;Oxford University Press, Oxford:
3. Torrance G W, Siegel J E, Luce B R. Framing and designing the cost-effectiveness analysis. Gold M R, Siegel J E, Russell L B. Cost-effectiveness in health and medicine. 1996;54-81 Oxford University Press, Oxford:
4. Elixhauser A, Luce B R, Taylor W R. Health care CBA/CEA: an update in the growth and composition of the literature. Med Care. 31:1993;js1-js11.
5. .Pritchard, C. Trends in economic evaluation. OHE briefing. London: Office of Health Economics1998;36.
6. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. 1995;Australian Government Publishing Service, Canberra:
7. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd ed. 1997;Canadian Coordinating Office for Health Technology Assessment, Ottawa:
8. Stigglebout A M, Kiebert G M, de Haes J CJM. Surveillance versus adjuvant chemotherapy in Stage I nonseminomatous testicular cancer: a decision analysis. Eur J Cancer. 32A:1996;2267-2274.
9. Chamberlain J, Melia J, Moss S. Report prepared for the Health Technology Assessment Panel of the NHS Executive on diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol. 79:1997;1-33.
10. Norum J, Angelsen V. Chemotherapy in gastric cancer: an economic evaluation of FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5- fluorouracil) regimens. J Chemother. 7:1995;455-459.
11. Zbrozek A S, Cantor S B, Cardenas M P. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm. 51:1994;1555-1563.
12. Kane R L, Wales J, Bernstein L. A randomised controlled trial of hospice care. Lancet. i:1984;890-894.
13. Russell L B, Gold M R, Siegel J E. for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA. 276:1996;1172-1177.
14. Weinstein M C, Siegel J E, Gold M R. for the Panel on the Cost-Effectiveness of Health and Medicine. Recommendation of the panel on cost-effectiveness in health and medicine. JAMA. 276:1996;1253-1258.
15. Siegel J E, Weinstein M C, Russell L B. for the Panel on the Cost-Effectivness in Health and Medicine. Recommendations for reporting cost-effectivness analysis. JAMA. 276:1996;1339-1341.
16. Luce B R, Manning W G, Siegel J E. Estimating costs in cost-effectiveness analysis. Gold M R, Siegel J E, Russell L B. Cost-effectiveness in health and medicine. 1996;176-213 Oxford University Press, Oxford:
17. Aaronson N K, Ahmedzai S, Bergman B. The European Organisation for Research and Treatment of Cancer QLQ-30: a quality of life instrument for use with international clinical trials in oncology. J Natl Cancer Inst. 85:1993;365-376.
18. Ibbotson T, Maguire P, Selby P. Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer. 30A:1994;37-40.
19. Torrance G W. Measurement of health state utilities for economic appraisal - a review. J Health Econ. 5:1986;1-30.
20. Brooks R. EuroQol: the current state of play. Health Policy. 37:1996;53-72.
21. Norum J, Vonen B, Olsen J A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 8:1997;65-70.
22. Ortega A, Dranitsaris G, Sturgeon J. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol. 66:1997;454-463.
23. Kaplan R M. Quality of life assessment for cost/utility studies in cancer. Cancer Treat Rev. 19:1993;85-96.
24. Gelber R D, Goldhirsch A, Cole B F. A qualityadjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 88:1996;1039-1045.
25. Godhirsch A, Gelber R D, Simes J. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol. 7:1989;36-44.
26. Brown M L, Nayfield S G, Shibley L M. Adjuvant therapy for Stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 86:1994;424-430.
27. Gerard K, Mooney G. QALY league tables: handle with care. Health Econ. 2:1993;59-64.
28. Drummond M F, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 37:1993;33-40.
29. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ. 306:1993;570-572.
30. Buxton M J, Drummond M F, van Hout B A. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6:1997;217-227.
31. Drummond M, O'Brien B. Clinical importance, statistical significance and the assessment of economic and qualityof- life outcomes. Health Econ. 2:1993;205-212.
32. Torgerson D J, Ryan M, Ratcliffe J. Economics in sample size determination for clinical trials. Q J Med. 88:1995;517-521.
33. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manage Sci. 1:1998;133-140.
34. Hutton J, Brown R, Borowitz M. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics. 9:1996;8-22.
35. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 3:1994;95-104.
36. Sculpher M, Drummond M, Buxton M. The interative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 2:1997;26-30.
37. Townsend J, Buxton M. Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy. 39:1997;181-194.
38. .Treasury, H, M. Appraisal and evaluation in central government. Treasury guidance. London: MHSO,1997.
39. Parsonage M, Neuberger H. Discounting health benefits. Health Econ. 1:1992;71-76.
40. Cairns J. Discounting and health benefits: another perspective. Health Econ. 1:1992;76-79.
41. .Department of Health. Policy appraisal and health. A guide from the Department of Health. London: DoH,1995.
42. Lipscomb J, Weinstein M C, Torrance G W. Time preference. Gold M R, Siegel J E, Russell L B. Cost-effectiveness in health and medicine. 1996;214-246 Oxford University Press, Oxford: